Cutting Through the Noise: Market Evolution and Pathways to Access for COVID-19 Vaccines and Therapeutics 

Summary

Avalere experts discussed the marketplace for COVID-19 vaccines and therapeutics, including key decision points for regulatory pathways, pricing, and distribution scenarios for optimal US and EX-US market access. 

Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.

Access Recording

Access Webinar Slides

With hundreds of vaccine and therapeutic candidates in the pipeline, planning ahead for patient access is vital. This uncharted territory provokes important questions about regulatory pathways, pricing, government procurement, coverage, access, distribution, and more.  Avalere experts explored these questions and tipping points, as well as the necessary market access strategies.

Key Topics

FDA regulatory considerations and downstream implications 
Coverage and access challenges 
Pricing, procurement, and distribution scenarios
Potential 2020 election impacts on the COVID-19 response

Panelists

Moderator

Elizabeth Carpenter , President

As president of Avalere Health, Elizabeth Carpenter is responsible for the firm’s consulting, sales, and operational functions.

Speaker

Kelly L. George , Principal, Market Access & Reimbursement

Kelly L. George, PhD, RAC, supports clients in navigating the FDA policy environment for the development and lifecycle of drugs and biologics.

Speaker

Richard Hughes IV , Managing Director

Richard Hughes IV leads Avalere’s vaccines team, which supports clients with vaccine policy, market access and evidence strategies.

Speaker

John C. Neal , Managing Director, Commercialization & Regulatory Strategy

John Neal partners with pharmaceutical and biotechnology clients to develop market access assessments and launch strategies to ensure successful asset commercialization.